Literature DB >> 11167377

IL4-R1 (5q31-q33) and FcepsilonRI-betaca (11q13) markers and atopy: a case/control study in a spanish population.

M J Torres-Galván1, J Quiralte, J J Pestano, N Ortega, C Blanco, R Castillo, T Carrillo, P Pérez-Aciego, F Sánchez-García.   

Abstract

BACKGROUND: Rhinoconjunctivitis and bronchial asthma are atopic diseases with a high prevalence in the Canary Islands (Spain). Given that the most prevalent allergen is the house-dust mite Dermatophagoides pteronyssinus, early detection of genetically susceptible subjects would allow the application of preventive measures. The objective was to investigate the possible association of IL4-R1 (chromosome 5q31-q33) and FcepsilonRI-betaca (chromosome 11q13) markers with the atopic disease in our population.
METHODS: We performed a case/control study in which patients were recruited on the basis of diagnosis of rhinoconjunctivitis and/or bronchial asthma, and positive skin prick test to D. pteronyssinus. Analysis of IL4-R1 and FcepsilonRI-betaca microsatellites was carried out by PCR and electrophoresis in acrylamide gels.
RESULTS: We have not found evidence of association between IL4-R1 and FcepsilonRI-betaca markers and atopic disease in our population. In addition, these markers have shown a high percentage of homozygosis.
CONCLUSIONS: IL4-R1 and FcepsilonRI-betaca markers have not proved to be useful genetic markers for linkage or association studies in our population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11167377     DOI: 10.1034/j.1398-9995.2001.056002159.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  2 in total

1.  A meta-analysis of Th2 pathway genetic variants and risk for allergic rhinitis.

Authors:  Supinda Bunyavanich; Josef Shargorodsky; Juan C Celedón
Journal:  Pediatr Allergy Immunol       Date:  2011-02-10       Impact factor: 6.377

Review 2.  Genomics and proteomics of allergic disease.

Authors:  Masako Toda; Santa Jeremy Ono
Journal:  Immunology       Date:  2002-05       Impact factor: 7.397

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.